메뉴 건너뛰기




Volumn 4, Issue 3, 2013, Pages 308-318

Markers of resistance to anti-EGFR therapy in colorectal cancer

Author keywords

Anti epidermal growth factor receptor (anti EGFR); Colorectal cancer; Resistance

Indexed keywords

AMPHIREGULIN; B RAF KINASE; BIOLOGICAL MARKER; CAPECITABINE; CETUXIMAB; CIXUTUMUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIREGULIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SOMATOMEDIN C;

EID: 84995743878     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.3978/j.issn.2078-6891.2013.029     Document Type: Review
Times cited : (59)

References (77)
  • 2
    • 84995798458 scopus 로고    scopus 로고
    • Centers for Disease Control and Prevention: United States Cancer Statistics: US Cancer Statistics Working Group. Available online
    • Centers for Disease Control and Prevention: United States Cancer Statistics: US Cancer Statistics Working Group. Available online: http://www.cdc.gov/uscs, 2013.
    • (2013)
  • 3
    • 84877286724 scopus 로고    scopus 로고
    • Regorafenib for metastatic colorectal cancer
    • André T, Raymond E, de Gramont A. Regorafenib for metastatic colorectal cancer. Lancet 2013;381:1536-7.
    • (2013) Lancet , vol.381 , pp. 1536-1537
    • André, T.1    Raymond, E.2    de Gramont, A.3
  • 4
    • 84868225968 scopus 로고    scopus 로고
    • FDA approves aflibercept (Zaltrap) for metastatic colorectal cancer.
    • FDA approves aflibercept (Zaltrap) for metastatic colorectal cancer. Oncology (Williston Park) 2012;26:842, 873.
    • (2012) Oncology (Williston Park) , vol.26
  • 6
    • 79956298812 scopus 로고    scopus 로고
    • Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status
    • Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-9.
    • (2011) J Clin Oncol , vol.29 , pp. 2011-2019
    • Van Cutsem, E.1    Köhne, C.H.2    Láng, I.3
  • 7
    • 0024261027 scopus 로고
    • Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice
    • Aboud-Pirak E, Hurwitz E, Pirak ME, et al. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 1988;80:1605-11.
    • (1988) J Natl Cancer Inst , vol.80 , pp. 1605-1611
    • Aboud-Pirak, E.1    Hurwitz, E.2    Pirak, M.E.3
  • 8
    • 0032695910 scopus 로고    scopus 로고
    • Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP- 358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice
    • Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP- 358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999;291:739-48.
    • (1999) J Pharmacol Exp Ther , vol.291 , pp. 739-748
    • Pollack, V.A.1    Savage, D.M.2    Baker, D.A.3
  • 9
    • 44249111440 scopus 로고    scopus 로고
    • EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
    • Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2311-9.
    • (2008) J Clin Oncol , vol.26 , pp. 2311-2319
    • Sobrero, A.F.1    Maurel, J.2    Fehrenbacher, L.3
  • 10
    • 0035117355 scopus 로고    scopus 로고
    • Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
    • Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001;38:17-23.
    • (2001) Crit Rev Oncol Hematol , vol.38 , pp. 17-23
    • Yang, X.D.1    Jia, X.C.2    Corvalan, J.R.3
  • 11
    • 46249096899 scopus 로고    scopus 로고
    • Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK
    • Borner M, Koeberle D, Von Moos R, et al. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol 2008;19:1288-92.
    • (2008) Ann Oncol , vol.19 , pp. 1288-1292
    • Borner, M.1    Koeberle, D.2    Von Moos, R.3
  • 12
    • 78149250536 scopus 로고    scopus 로고
    • Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study
    • Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-705.
    • (2010) J Clin Oncol , vol.28 , pp. 4697-4705
    • Douillard, J.Y.1    Siena, S.2    Cassidy, J.3
  • 13
    • 84995758881 scopus 로고    scopus 로고
    • Information on the conditional approval of panitumumab (Vectibix) by the EMEA. Available online . (Accessed on April 20).
    • Information on the conditional approval of panitumumab (Vectibix) by the EMEA. Available online: www.emea.europa.eu/pdfs/human/press/pr/32370307en.pdf 2011. (Accessed on April 20).
    • (2011)
  • 15
    • 33746889808 scopus 로고    scopus 로고
    • A comprehensive pathway map of epidermal growth factor receptor signaling
    • Oda K, Matsuoka Y, Funahashi A, et al. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 2005;1:2005.0010. 16. Han CB, Li F, Ma JT, et al. Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review. Cancer Invest 2012;30:741-7.
    • (2005) Mol Syst Biol , vol.1 , pp. 20050010
    • Oda, K.1    Matsuoka, Y.2    Funahashi, A.3
  • 16
    • 84870717009 scopus 로고    scopus 로고
    • Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review
    • Han CB, Li F, Ma JT, et al. Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review. Cancer Invest 2012;30:741-7.
    • (2012) Cancer Invest , vol.30 , pp. 741-747
    • Han, C.B.1    Li, F.2    Ma, J.T.3
  • 17
    • 55249109460 scopus 로고    scopus 로고
    • Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data)
    • Tejpar S, Humblet M, Vermorken Y, et al. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data). J Clin Oncol 2008;26:4001.
    • (2008) J Clin Oncol , vol.26 , pp. 4001
    • Tejpar, S.1    Humblet, M.2    Vermorken, Y.3
  • 18
    • 44449101007 scopus 로고    scopus 로고
    • Correlation of efficacy to KRAS status (wt vs. mut) in patients (pts) with metastatic colorectal cancer (mCRC), treated with weekly (q1w) and q2w schedules of cetuximab combined with FOLFIRI
    • ASCO GI Cancers Symposium (January 25-27, 2008, Orlando, FL)
    • Tabernero J, Cervantes A, Ciardiello F. Correlation of efficacy to KRAS status (wt vs. mut) in patients (pts) with metastatic colorectal cancer (mCRC), treated with weekly (q1w) and q2w schedules of cetuximab combined with FOLFIRI. ASCO GI Cancers Symposium (January 25-27, 2008, Orlando, FL). 2008:abstr 435.
    • (2008) , pp. 435
    • Tabernero, J.1    Cervantes, A.2    Ciardiello, F.3
  • 19
    • 34247278727 scopus 로고    scopus 로고
    • Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
    • Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007;96:1166-9.
    • (2007) Br J Cancer , vol.96 , pp. 1166-1169
    • Di Fiore, F.1    Blanchard, F.2    Charbonnier, F.3
  • 20
    • 38649099966 scopus 로고    scopus 로고
    • KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
    • Lièvre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9.
    • (2008) J Clin Oncol , vol.26 , pp. 374-379
    • Lièvre, A.1    Bachet, J.B.2    Boige, V.3
  • 21
    • 78049341541 scopus 로고    scopus 로고
    • Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
    • De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010;304:1812-20.
    • (2010) JAMA , vol.304 , pp. 1812-1820
    • De Roock, W.1    Jonker, D.J.2    Di Nicolantonio, F.3
  • 22
    • 40149088765 scopus 로고    scopus 로고
    • KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
    • De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19:508-15.
    • (2008) Ann Oncol , vol.19 , pp. 508-515
    • De Roock, W.1    Piessevaux, H.2    De Schutter, J.3
  • 23
    • 79956310674 scopus 로고    scopus 로고
    • Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
    • Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011;22:1535-46.
    • (2011) Ann Oncol , vol.22 , pp. 1535-1546
    • Bokemeyer, C.1    Bondarenko, I.2    Hartmann, J.T.3
  • 24
    • 3242720345 scopus 로고    scopus 로고
    • Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer
    • Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
    • (2004) N Engl J Med , vol.351 , pp. 337-345
    • Cunningham, D.1    Humblet, Y.2    Siena, S.3
  • 25
    • 63849088630 scopus 로고    scopus 로고
    • Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
    • Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
    • (2009) N Engl J Med , vol.360 , pp. 1408-1417
    • Van Cutsem, E.1    Köhne, C.H.2    Hitre, E.3
  • 26
    • 34147103678 scopus 로고    scopus 로고
    • Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
    • Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64.
    • (2007) J Clin Oncol , vol.25 , pp. 1658-1664
    • Van Cutsem, E.1    Peeters, M.2    Siena, S.3
  • 27
    • 54949085398 scopus 로고    scopus 로고
    • K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    • Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
    • (2008) N Engl J Med , vol.359 , pp. 1757-1765
    • Karapetis, C.S.1    Khambata-Ford, S.2    Jonker, D.J.3
  • 28
    • 0034548712 scopus 로고    scopus 로고
    • K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression
    • Guerrero S, Casanova I, Farré L, et al. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 2000;60:6750-6.
    • (2000) Cancer Res , vol.60 , pp. 6750-6756
    • Guerrero, S.1    Casanova, I.2    Farré, L.3
  • 29
    • 84875742535 scopus 로고    scopus 로고
    • Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab
    • Peeters M, Douillard JY, Van Cutsem E, et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 2013;31:759-65.
    • (2013) J Clin Oncol , vol.31 , pp. 759-765
    • Peeters, M.1    Douillard, J.Y.2    Van Cutsem, E.3
  • 30
    • 34548238762 scopus 로고    scopus 로고
    • Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
    • Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-7.
    • (2007) J Clin Oncol , vol.25 , pp. 3230-3237
    • Khambata-Ford, S.1    Garrett, C.R.2    Meropol, N.J.3
  • 31
    • 79551580548 scopus 로고    scopus 로고
    • Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
    • Baker JB, Dutta D, Watson D, et al. Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br J Cancer 2011;104:488-95.
    • (2011) Br J Cancer , vol.104 , pp. 488-495
    • Baker, J.B.1    Dutta, D.2    Watson, D.3
  • 32
    • 20144381957 scopus 로고    scopus 로고
    • Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
    • Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-10.
    • (2005) J Clin Oncol , vol.23 , pp. 1803-1810
    • Chung, K.Y.1    Shia, J.2    Kemeny, N.E.3
  • 33
    • 17844362179 scopus 로고    scopus 로고
    • Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
    • Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005;6:279-86.
    • (2005) Lancet Oncol , vol.6 , pp. 279-286
    • Moroni, M.1    Veronese, S.2    Benvenuti, S.3
  • 34
    • 34548258303 scopus 로고    scopus 로고
    • Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab
    • Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007;25:3238-45.
    • (2007) J Clin Oncol , vol.25 , pp. 3238-3245
    • Sartore-Bianchi, A.1    Moroni, M.2    Veronese, S.3
  • 35
    • 33750615769 scopus 로고    scopus 로고
    • Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    • Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006;24:4914-21.
    • (2006) J Clin Oncol , vol.24 , pp. 4914-4921
    • Lenz, H.J.1    Van Cutsem, E.2    Khambata-Ford, S.3
  • 36
    • 41549097718 scopus 로고    scopus 로고
    • EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients
    • Cappuzzo F, Finocchiaro G, Rossi E, et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 2008;19:717-23.
    • (2008) Ann Oncol , vol.19 , pp. 717-723
    • Cappuzzo, F.1    Finocchiaro, G.2    Rossi, E.3
  • 37
    • 53249123419 scopus 로고    scopus 로고
    • Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study
    • Personeni N, Fieuws S, Piessevaux H, et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res 2008;14:5869-76.
    • (2008) Clin Cancer Res , vol.14 , pp. 5869-5876
    • Personeni, N.1    Fieuws, S.2    Piessevaux, H.3
  • 38
    • 33646228635 scopus 로고    scopus 로고
    • KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
    • Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5.
    • (2006) Cancer Res , vol.66 , pp. 3992-3995
    • Lièvre, A.1    Bachet, J.B.2    Le Corre, D.3
  • 39
    • 84874167463 scopus 로고    scopus 로고
    • EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis
    • Jiang Z, Li C, Li F, et al. EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis. PLoS One 2013;8:e56205.
    • (2013) PLoS One , vol.8
    • Jiang, Z.1    Li, C.2    Li, F.3
  • 40
    • 77955277111 scopus 로고    scopus 로고
    • Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapyrefractory metastatic colorectal cancer: a retrospective consortium analysis
    • De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapyrefractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62.
    • (2010) Lancet Oncol , vol.11 , pp. 753-762
    • De Roock, W.1    Claes, B.2    Bernasconi, D.3
  • 41
    • 73349114941 scopus 로고    scopus 로고
    • KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial
    • Richman SD, Seymour MT, Chambers P, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009;27:5931-7.
    • (2009) J Clin Oncol , vol.27 , pp. 5931-5937
    • Richman, S.D.1    Seymour, M.T.2    Chambers, P.3
  • 42
    • 77954215850 scopus 로고    scopus 로고
    • Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab
    • Tol J, Dijkstra JR, Klomp M, et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 2010;46:1997-2009.
    • (2010) Eur J Cancer , vol.46 , pp. 1997-2009
    • Tol, J.1    Dijkstra, J.R.2    Klomp, M.3
  • 43
    • 84861432557 scopus 로고    scopus 로고
    • Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study
    • Tveit KM, Guren T, Glimelius B, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012;30:1755-62.
    • (2012) J Clin Oncol , vol.30 , pp. 1755-1762
    • Tveit, K.M.1    Guren, T.2    Glimelius, B.3
  • 44
    • 57449095367 scopus 로고    scopus 로고
    • Wildtype BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
    • Di Nicolantonio F, Martini M, Molinari F, et al. Wildtype BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-12.
    • (2008) J Clin Oncol , vol.26 , pp. 5705-5712
    • Di Nicolantonio, F.1    Martini, M.2    Molinari, F.3
  • 45
    • 22244472992 scopus 로고    scopus 로고
    • Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers
    • Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65:6063-9.
    • (2005) Cancer Res , vol.65 , pp. 6063-6069
    • Samowitz, W.S.1    Sweeney, C.2    Herrick, J.3
  • 46
    • 1642535480 scopus 로고    scopus 로고
    • BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer
    • Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004;10:191-5.
    • (2004) Clin Cancer Res , vol.10 , pp. 191-195
    • Deng, G.1    Bell, I.2    Crawley, S.3
  • 47
    • 0141593677 scopus 로고    scopus 로고
    • BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair
    • Wang L, Cunningham JM, Winters JL, et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003;63:5209-12.
    • (2003) Cancer Res , vol.63 , pp. 5209-5212
    • Wang, L.1    Cunningham, J.M.2    Winters, J.L.3
  • 48
    • 84863230465 scopus 로고    scopus 로고
    • Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
    • Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012;483:100-3.
    • (2012) Nature , vol.483 , pp. 100-103
    • Prahallad, A.1    Sun, C.2    Huang, S.3
  • 49
    • 34250340783 scopus 로고    scopus 로고
    • Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models
    • Ji H, Wang Z, Perera SA, et al. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res 2007;67:4933-9.
    • (2007) Cancer Res , vol.67 , pp. 4933-4939
    • Ji, H.1    Wang, Z.2    Perera, S.A.3
  • 50
    • 68749119351 scopus 로고    scopus 로고
    • KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
    • Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009;101:715-21.
    • (2009) Br J Cancer , vol.101 , pp. 715-721
    • Loupakis, F.1    Ruzzo, A.2    Cremolini, C.3
  • 51
    • 79952392909 scopus 로고    scopus 로고
    • Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer
    • Vaughn CP, Zobell SD, Furtado LV, et al. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 2011;50:307-12.
    • (2011) Genes Chromosomes Cancer , vol.50 , pp. 307-312
    • Vaughn, C.P.1    Zobell, S.D.2    Furtado, L.V.3
  • 52
    • 68149165771 scopus 로고    scopus 로고
    • Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
    • Souglakos J, Philips J, Wang R, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 2009;101:465-72.
    • (2009) Br J Cancer , vol.101 , pp. 465-472
    • Souglakos, J.1    Philips, J.2    Wang, R.3
  • 53
    • 78049313767 scopus 로고    scopus 로고
    • Oncogenic RAF: a brief history of time
    • Solit D, Rosen N. Oncogenic RAF: a brief history of time. Pigment Cell Melanoma Res 2010;23:760-2.
    • (2010) Pigment Cell Melanoma Res , vol.23 , pp. 760-762
    • Solit, D.1    Rosen, N.2
  • 54
    • 84860540538 scopus 로고    scopus 로고
    • Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas
    • Migliardi G, Sassi F, Torti D, et al. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res 2012;18:2515-25.
    • (2012) Clin Cancer Res , vol.18 , pp. 2515-2525
    • Migliardi, G.1    Sassi, F.2    Torti, D.3
  • 55
    • 84860634396 scopus 로고    scopus 로고
    • PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    • Mao C, Yang ZY, Hu XF, et al. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol 2012;23:1518-25.
    • (2012) Ann Oncol , vol.23 , pp. 1518-1525
    • Mao, C.1    Yang, Z.Y.2    Hu, X.F.3
  • 56
    • 40649096375 scopus 로고    scopus 로고
    • Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
    • Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A 2008;105:2652-7.
    • (2008) Proc Natl Acad Sci U S A , vol.105 , pp. 2652-2657
    • Zhao, L.1    Vogt, P.K.2
  • 57
    • 65649086786 scopus 로고    scopus 로고
    • PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer
    • Prenen H, De Schutter J, Jacobs B, et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009;15:3184-8.
    • (2009) Clin Cancer Res , vol.15 , pp. 3184-3188
    • Prenen, H.1    De Schutter, J.2    Jacobs, B.3
  • 58
    • 84873027952 scopus 로고    scopus 로고
    • Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
    • Pentheroudakis G, Kotoula V, De Roock W, et al. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer 2013;13:49.
    • (2013) BMC Cancer , vol.13 , pp. 49
    • Pentheroudakis, G.1    Kotoula, V.2    De Roock, W.3
  • 59
    • 57349194139 scopus 로고    scopus 로고
    • Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
    • Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008;14:1351-6.
    • (2008) Nat Med , vol.14 , pp. 1351-1356
    • Engelman, J.A.1    Chen, L.2    Tan, X.3
  • 60
    • 58249120506 scopus 로고    scopus 로고
    • Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance
    • Ihle NT, Lemos R Jr, Wipf P, et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 2009;69:143-50.
    • (2009) Cancer Res , vol.69 , pp. 143-150
    • Ihle, N.T.1    Lemos, R.Jr.2    Wipf, P.3
  • 62
    • 11144358645 scopus 로고    scopus 로고
    • High frequency of mutations of the PIK3CA gene in human cancers
    • Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
    • (2004) Science , vol.304 , pp. 554
    • Samuels, Y.1    Wang, Z.2    Bardelli, A.3
  • 63
    • 21144457217 scopus 로고    scopus 로고
    • Functional analysis of PIK3CA gene mutations in human colorectal cancer
    • Ikenoue T, Kanai F, Hikiba Y, et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005;65:4562-7.
    • (2005) Cancer Res , vol.65 , pp. 4562-4567
    • Ikenoue, T.1    Kanai, F.2    Hikiba, Y.3
  • 64
    • 0030936323 scopus 로고    scopus 로고
    • PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
    • Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7.
    • (1997) Science , vol.275 , pp. 1943-1947
    • Li, J.1    Yen, C.2    Liaw, D.3
  • 65
    • 0033984095 scopus 로고    scopus 로고
    • Involvement of PTEN mutations in the genetic pathways of colorectal cancerogenesis
    • Guanti G, Resta N, Simone C, et al. Involvement of PTEN mutations in the genetic pathways of colorectal cancerogenesis. Hum Mol Genet 2000;9:283-7.
    • (2000) Hum Mol Genet , vol.9 , pp. 283-287
    • Guanti, G.1    Resta, N.2    Simone, C.3
  • 66
    • 0035965935 scopus 로고    scopus 로고
    • PTEN gene mutations in colorectal cancers displaying microsatellite instability
    • Shin KH, Park YJ, Park JG. PTEN gene mutations in colorectal cancers displaying microsatellite instability. Cancer Lett 2001;174:189-94.
    • (2001) Cancer Lett , vol.174 , pp. 189-194
    • Shin, K.H.1    Park, Y.J.2    Park, J.G.3
  • 67
    • 2342504508 scopus 로고    scopus 로고
    • Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers
    • Goel A, Arnold CN, Niedzwiecki D, et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res 2004;64:3014-21.
    • (2004) Cancer Res , vol.64 , pp. 3014-3021
    • Goel, A.1    Arnold, C.N.2    Niedzwiecki, D.3
  • 68
    • 62449302407 scopus 로고    scopus 로고
    • PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies
    • Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009;69:1851-7.
    • (2009) Cancer Res , vol.69 , pp. 1851-1857
    • Sartore-Bianchi, A.1    Martini, M.2    Molinari, F.3
  • 69
    • 42149083899 scopus 로고    scopus 로고
    • Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers
    • Barault L, Veyrie N, Jooste V, et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008;122:2255-9.
    • (2008) Int J Cancer , vol.122 , pp. 2255-2259
    • Barault, L.1    Veyrie, N.2    Jooste, V.3
  • 71
    • 80052591747 scopus 로고    scopus 로고
    • Activation of ERBB2 signaling causes resistance to the EGFRdirected therapeutic antibody cetuximab
    • Yonesaka K, Zejnullahu K, Okamoto I, et al. Activation of ERBB2 signaling causes resistance to the EGFRdirected therapeutic antibody cetuximab. Sci Transl Med 2011;3:99ra86.
    • (2011) Sci Transl Med , vol.3
    • Yonesaka, K.1    Zejnullahu, K.2    Okamoto, I.3
  • 72
    • 84862999938 scopus 로고    scopus 로고
    • Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
    • Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012;486:532-6.
    • (2012) Nature , vol.486 , pp. 532-536
    • Misale, S.1    Yaeger, R.2    Hobor, S.3
  • 73
    • 0036793827 scopus 로고    scopus 로고
    • Blockade of insulinlike growth factor I receptor function inhibits growth and angiogenesis of colon cancer
    • Reinmuth N, Liu W, Fan F, et al. Blockade of insulinlike growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res 2002;8:3259-69.
    • (2002) Clin Cancer Res , vol.8 , pp. 3259-3269
    • Reinmuth, N.1    Liu, W.2    Fan, F.3
  • 74
    • 54249155585 scopus 로고    scopus 로고
    • Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor
    • Hu YP, Patil SB, Panasiewicz M, et al. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor. Cancer Res 2008;68:8004-13.
    • (2008) Cancer Res , vol.68 , pp. 8004-8013
    • Hu, Y.P.1    Patil, S.B.2    Panasiewicz, M.3
  • 75
    • 0242288111 scopus 로고    scopus 로고
    • Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment
    • Bohula EA, Playford MP, Macaulay VM. Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment. Anticancer Drugs 2003;14:669-82.
    • (2003) Anticancer Drugs , vol.14 , pp. 669-682
    • Bohula, E.A.1    Playford, M.P.2    Macaulay, V.M.3
  • 76
    • 77957962308 scopus 로고    scopus 로고
    • Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer
    • Reidy DL, Vakiani E, Fakih MG, et al. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol 2010;28:4240-6.
    • (2010) J Clin Oncol , vol.28 , pp. 4240-4246
    • Reidy, D.L.1    Vakiani, E.2    Fakih, M.G.3
  • 77
    • 54249117292 scopus 로고    scopus 로고
    • Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors
    • Buck E, Eyzaguirre A, Rosenfeld-Franklin M, et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 2008;68:8322-32.
    • (2008) Cancer Res , vol.68 , pp. 8322-8332
    • Buck, E.1    Eyzaguirre, A.2    Rosenfeld-Franklin, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.